Fibromyalgia — all decisions

The Board granted service connection for chronic fatigue syndrome, fibromyalgia, chronic diarrhea, and hypertension. Service connection was denied for an acquired psychiatric disorder and various musculoskeletal disorders.

The Board denied service connection for asthma, hypertension, and vertigo. The claims for bilateral lower extremity radiculopathy were also denied as not secondary to a service-connected disability. Some claims for various musculoskeletal conditions of the cervical spine, shoulders, elbows, wrists, hips, knees, ankles, feet, and fibromyalgia are remanded for further development.

The Board denied increased ratings for fibromyalgia, duodenal ulcer, and PTSD with TBI, but granted service connection for left ear hearing loss disability.

The Board granted service connection for fibromyalgia and allergic rhinitis, effective January 16, 2024.

The Board granted service connection for migraine headaches, PTSD (claimed as a mental disorder), and fibromyalgia. The claims for gastrointestinal problems, Meniere's disease, hemorrhoids, rhinitis, and sinusitis were remanded.

The Board granted earlier effective dates for the awards of service connection for sinusitis and rhinitis, as well as initial 30 percent disability ratings for these conditions. The appeal was also remanded for further development on several other issues.

The Board denied service connection for chronic fatigue syndrome, left great toenail condition, diabetes mellitus due to anthrax vaccine, fibromyalgia, and right and left knee bursitis.

The Board granted service connection for multiple conditions, including spondylolisthesis or segmental instability (DJD spondylolisthesis L-5 S1), radiculopathy of the sciatic nerve, paralysis of the ulnar nerve, acromioclavicular joint arthritis, left ankle tendonitis, right knee patellofemoral syndrome, left knee patellofemoral syndrome, bilateral feet with plantar fasciitis, fibromyalgia, pituitary macroadenoma, diabetes mellitus type II, and renal failure.

The appeal for irritable bowel syndrome, fibromyalgia, and sleep apnea has been withdrawn by the appellant.

The Board granted an initial 60 percent rating for psoriasis and a 20 percent rating for fibromyalgia, effective March 4, 2022, while denying a higher rating for the left ankle disability.

The Board remands the claims for service connection for various conditions, including hyperacusis, vertigo, chronic pain condition, fibromyalgia, psychiatric disorder, fatigue-related issues, and low back condition, to correct duty to assist errors.

The veteran withdrew the appeal for service connection for fibromyalgia and claims for increased ratings for left and right knee patellofemoral syndrome.

The Board granted an effective date of November 16, 2022, for the grant of service connection for fibromyalgia as a secondary condition to the Veteran's service-connected posttraumatic stress disorder (PTSD).

The Board granted service connection for fibromyalgia, a medically unexplained chronic multi-symptom illness, on a presumptive basis due to the Veteran's service in Southwest Asia during the Persian Gulf War.

The Board remands the claim for service connection for fibromyalgia to correct a pre-decisional duty to assist error.

The appeal was dismissed due to the death of the appellant.

The Board dismissed the appeals for service connection of various conditions as they were premature, and denied service connection for diabetes mellitus, type II and a migraine headache disability.

The Board denied entitlement to a total disability rating based on individual unemployability (TDIU) due solely to posttraumatic stress disorder (PTSD) and special monthly compensation (SMC) at the statutory housebound rate.

The Board granted the petition to reopen the claim of service connection for a right foot disorder and remanded claims for service connection for left foot disorder, pes planus (flat foot) and hallux valgus, as well as fibromyalgia.

The Board denied service connection for bilateral hearing loss and denied increased ratings for fibromyalgia and chronic fatigue syndrome.